NEUROIMMUNOLOGY SYMPOSIUM

PROGRAMME

5-6 NOVEMBER 2026.

PODGORICA, MONTENEGRO

UNCG
UDRUŽENJE NEUROLOGA CRNE GORE

20 OBNOVA NEZAVISNOSTI CRNE GORE 2006–2026

55 CRNOGORSKA AKADEMIJA NAUKA I UMJETNOSTI 1971–2026

2006 XX 2026
DA JE VJEČNA CRNA GORA

Organizers

Montenegrin Association of Neurologists
Montenegrin Academy of Sciences and Arts

Organizing Committee

Montenegrin Association of Neurologists
Mladen Debeljević
Ljiljana Radulović
Jevto Eraković
Milovan Roganović

Montenegrin Academy of Sciences and Arts
Vaso Antunović
Goran Nikolić
Ranko Lazović
Jelena Pajović

Venue

Montenegrin Academy of Sciences and Arts
Rista Stijovića 5
81000 Podgorica, Montenegro

Technical Organizer

Congress Travel d.o.o.
Studentska, lamela 3-5,
81000 Podgorica,
Montenegro

web: www.congresstravel.me
e-mail: info@congresstravel.me


The Symposium is accrediated by the Montenegrin Medical Chamber.



OCREVUS is the only aCD20 approved for both RMS and PPMS1,2 with >11 years of clinical experience[1]

With its convenient ~10-minute*, twice-yearly injection delivered by an HCP, OCREVUS SC facilitates the treatment experience, allowing patients to forget about their MS treatment for six months[2]

This convenience leads to a superior patient experience with at least 98% of patients preferring OCREVUS SC to previous DMTs[3]



Skraćenice: SC - subkutano; RMS - relapsna multipla skleroza; PPMS - primarno progresivna multipla skleroza, aCD20 - anti-CD20
Literatura:1. Newsome et al. Poster presented at ACTRIMS 2026 (P125); 2. Ocrevus sažetak karakteristika lijeka, dostupno na https://cinmed.me/registar-humanih-lijekova/ ; 3.Newsome SD et al. ECTRIMS 2025; Presentation P307
* Stvarno vrijeme primjene injekcije može varirati.
Internacionalni nezaštićen naziv farmaceutske/ih supstance/i: Okrelizumab
Nosilac dozvole: Hoffmann-La Roche Ltd Representative Office | Cetinjska 11, The Capital Plaza 81 000 Podgorica; Tel:+ 382 20 241 823; Roche Crna Gora, montenegro.info@roche.com
Broj i datum dozvole za stavljanje lijeka u promet: 2030/25/2198 – 974 od 29.05.2025.
Datum revizije teksta SmPC-a: Oktobar, 2025. godine
Režim izdavanja lijeka: Lijek se izdaje samo na ljekarski recept
Odobreni Sažetak karakteristika lijeka (SmPC): Humani lijek - Cinmed
Važna napomena: Prije propisivanja leka, detaljno proučiti u cjelosti Sažetak karakteristika lijeka.
Cjelokupan sadržaj uživa autorsko-pravnu zaštitu, © ROCHE 2026. Sadržaj ne smije biti kopiran, reprodukovan, distribuiran, objavljen, mijenjan, prenijet ili prikazivan bez prethodne saglasnosti autora.
SAMO ZA STRUČNU JAVNOST
Novembar 2026 I M-ME-00001445

OCREVUS®
ocrelizumab
Subcutaneous injection

DAY 1

5 November 2026

NEUROIMMUNOLOGICAL DISORDERS OF THE CENTRAL NERVOUS SYSTEM

08:30 - 09:00

REGISTRATION

09:00 - 09:30

OPENING CEREMONY AND WELCOME ADDRESSES

09:30 - 11:30

ADULT MULTIPLE SCLEROSIS

CHAIRS: Lj. Radulović (MNE), T. Berger (AUT)

09:30 - 09:50	T. Berger (AUT): New Pathophysiological Concepts in Multiple Sclerosis: Recent Insights into the Role of Epstein-Barr Virus
09:50 - 10:10	J. Drulović (SRB): Redefining Multiple Sclerosis and Potential Pitfalls to Anticipate Following the Adoption of the New Criteria
10:10 - 10:30	Lj. Radulović (MNE): Individualized Approach to the Treatment of Patients with Multiple Sclerosis
10:30 - 10:50	O. Tamaš (SRB): Multiple Sclerosis and Cognition: Recognizing, Monitoring and Acting Early
10:50 - 11:10	E. Mehmedika Suljić (BIH): Multiple Sclerosis and Depression
11:10 - 11:20	C. Kerala (MKD): Atypical Inflammatory Demyelinating Syndromes of the CNS: A Case Report
11:20 - 11:30	Discussion

11:30 - 12:00

COFFEE BREAK

12:00 - 13:45

NMOSD AND MOGAD

CHAIRS: Z. Idrizović (MNE), V. Suknjaja (SRB)

12:00 - 12:30	A. Siva (TUR): MS, NMOSD or MOGAD? Navigating Diagnostic Pitfalls
12:30 - 12:50	Š. Mesaroš (SRB): What Can We Expect in the Near Future in NMOSD and MOGAD?
12:50 - 13:10	T. Petkovska Boshkova (MKD): Current Treatment Strategies in MOG Antibody-Associated Disease (MOGAD)
13:10 - 13:30	S. Butković Soldo (CRO): Rehabilitation of Patients with Demyelinating Diseases of the Central Nervous System
13:30 - 13:45	Discussion

13:45 - 14:35

LUNCH

14:35 - 16:05

PEDIATRIC MULTIPLE SCLEROSIS

CHAIRS: J. Jančić (SRB), K. Rostasy (GER)

14:35 - 14:55	K. Rostasy (GER): New Insights into Pediatric Neuroimmunological Diseases
14:55 - 15:15	J. Jančić (SRB): Beyond Physical Disability: Cognitive Impairment in Children and Adolescents with Multiple Sclerosis
15:15 - 15:35	N. Bizjak (SLO): Advances in Therapeutic Strategies in Demyelinating DiseasesNervous System
15:35 - 15:45	Lj. Globarević (MNE): Treatment of Pediatric MS Patients in Montenegro
15:45 - 15:55	B. Nikolić (SRB): Pediatric Onset Multiple Sclerosis: From Clinical Presentation to Treatment
15:55 - 16:05	Discussion

16:05 - 16:30

COFFEE BREAK

16:30 - 18:00

OTHER AUTOIMMUNE DISORDERS OF THE CNS

CHAIRS: A. Ristić (SRB), L. Sakalaš (SRB)

16:30 - 16:50	N. Grigoriadis (GRE): Autoimmune Encephalitis: A Diagnostic Algorithm
16:50 - 17:10	P. Rommer (AUT): Acute and Long-Term Treatment Strategies in Autoimmune Encephalitis
17:10 - 17:30	S. Vujisić (MNE): Seizures as a Manifestation of Autoimmune Encephalitis
17:30 - 17:50	M. Marković Vlaisavljević (MNE): Systemic Connective Tissue Diseases Affecting the Central Nervous System
17:50 - 18:00	Discussion

18:00 - 18:15

CLOSING REMARKS

20:00 - 00:00

DINNER



MAVENCLAD®
kladribin tablete

SAMO ZA STRUČNU JAVNOST


ME-MAV-00131, Februar 2026.

This symposium is supported by an educational grant from

NOVARTIS

15 GODINA DOKAZANE EFIKASNOSTI[1]

MNOGO TOGA SE MOŽE PROMIJENITI ZA 15 GODINA



Referenca: Butzkueven H, Kappos L, Wiendl H, Trojano M, Spelman T, Greco A, et al. **TYSABRI™ Observacioni program (TOP)** je najveća dugoročna opservaciona studija lijeka TYSABRI za relapsno-remitentnu multiplu sklerozu (RRMS) u uslovima svakodnevne kliničke prakse. U studiji je na globalnom nivou uključeno više od 6.300 pacijenata, koji su se liječili lijekom TYSABRI™ u medijani od 9,7 godina. Neki pacijenti nastavljaju liječenje lijekom TYSABRI duže od 15 godina.

ME-TYS-1026-001 SAMO ZA STRUČNU JAVNOST
Medis Pharma d.o.o. Beograd, Milutina Milankovića 11b, 11070 Novi Beograd

MEDIS Therapeutics

TYSABRI™

SAMO ZA STRUČNU JAVNOST

teva

Manje migrena za više trenutaka



AJOVY® je indikovan za profilaksu migrene kod odraslih koji imaju migrenu najmanje 4 dana mjesečno.[1]

Otkrijte šta stope terapijskog odgovora na AJOVY® mogu značiti za vaše pacijente koji boluju od migrene

Ivanova rođendanska zabava

- ◯ Ne dolazim, moja migrena želi da ležim u mraku
- ✓ Da, dolazim

▼ Ovaj lijek je pod dodatnim praćenjem. Time se omogućava brzo otkrivanje novih bezbjednosnih informacija. Od zdravstvenih radnika se traži da prijave svaku sumnju na neželjenu reakciju na ovaj lijek. Uputstvo za prijavljivanje dostupno je na **www.cinmed.me**

Reference: 1. Sažetak karakteristika lijeka za AJOVY® odobren Januar 2023. **Napomena:** Upućujemo zdravstvene radnike na posljednji cjelokupni sažetak karakteristika lijeka i uputstvo o lijeku AJOVY®, koji je dostupan na internet stranici Instituta za lijekove i medicinska sredstva Crne Gore (http://www.cinmed.me). **Način izdavanja:** na recept, u apoteci. **Nosilac dozvole:** Evropa Lek Pharma d.o.o. Podgorica, Kritskog odreda 4/1, 81000 Podgorica, Crna Gora. **Broj i datum dozvole:** Ajovy, rastvor za injekciju u napunjenom injekcionom penu: 2030/23/151 od 8.01.2023. godine. **Datum pripreme materijala:** Oktobar 026. **Broj odobrenja:** AJO-RS-00179

AJOVY® ▼
(fremanezumab)
rastvor za injekciju 225 mg / 1,5 ml
u napunjenom injekcionom penu

DAY 2

6 November 2026

NEUROIMMUNOLOGICAL DISORDERS OF THE PERIPHERAL NERVOUS SYSTEM

08:30 - 09:00

REGISTRATION

09:00 - 10:50

NEUROMUSCULAR TRANSMISSION AND SYSTEMIC NEUROIMMUNOLOGICAL DISEASES - THE ERA OF TARGETED IMMUNOTHERAPY

CHAIRS: M. Debeljević (MNE), S. Perić (SRB)

09:00 - 09:20	Y. Parman (TUR): Myasthenia Gravis – Treatment Algorithm 2026
09:20 - 09:40	S. Perić (SRB): FcRn Inhibitors and Complement Inhibitors – Their Role in Therapy
09:40 - 10:00	M. Debeljević (MNE): Lambert–Eaton Myasthenic Syndrome – Treatment and Oncological Screening
10:00 - 10:20	S. Rajić (SRB): Autoimmune Myopathies (IMNM, Dermatomyositis) – Biological Therapy in Clinical Practice
10:20 - 10:40	A. Korać (MNE): From Failure of Conventional Therapy to Complement Inhibition: A Case Report of Refractory Myasthenia Gravis
10:40 - 10:50	Discussion

10:50 - 11:15

COFFEE BREAK

11:15 - 12:45

ACUTE AUTOIMMUNE NEUROPATHIES - EARLY INTERVENTION AND PROGNOSIS

CHAIRS: I. Stolić (MNE), A. Kuqo (ALB)

11:15 - 11:35	A. Kuqo (ALB): Guillain–Barré Syndrome – Early Treatment Algorithm (IVIG vs. Plasma Exchange
11:35 - 11:55	B. Vujović (MNE): Axonal Forms of GBS and Therapeutic Challenges
11:55 - 12:15	I. Stolić (MNE): Relapse and Treatment-Related Fluctuation – How Should We Manage It?
12:15 - 12:35	A. Mehičević (BIH): Sensory-Predominant Variants of Guillain-Barré Syndrome: A Diagnostic Challenge and the Experience of the Neurology Clinic, Clinical Center of the University of Sarajevo, over the Past 12 Months
12:35 - 12:45	Discussion

12:45 - 14:25

CHRONIC IMMUNE-MEDIATED NEUROPATHIES - PERSONALIZED THERAPY

CHAIRS: J. Eraković (MNE), B. Koritnik (SLO)

12:45 - 13:05	S. Podnar (SLO): CIDP – Current Diagnostic Criteria and Treatment Sequencing
13:05 - 13:25	B. Koritnik (SLO): Paranodal Autoimmune Nodopathies – NF155, CNTN1, CASPR1: Therapeutic Approach
13:25 - 13:45	A. Tela (MNE): Subcutaneous Immunoglobulins and Long-Term Maintenance Strategy
13:45 - 14:05	I. Božović (SRB): Refractory CIDP – When and How to Use Rituximab?
14:05 - 14:15	H. Jatić (BIH): Lewis–Sumner Syndrome (MADSAM): A Diagnostic Challenge – A Case Report
14:15 - 14:25	Discussion

14:25 - 14:30

CLOSING REMARKS

14:30 - 15:30

LUNCH

SPONZORI

Zlatni sponzor

Roche

Srebrni sponzor

MERCK

Bronzani sponzori

MEDIS Therapeutics

Actavis | teva

Sponzori

AstraZeneca

d.o.o. Medica PODGORICA

MEY PHARM

wörwag PHARMA

FARMONT

Goodwill

Sun Wave Pharma
Making Tomorrow Healthier

PHARMASWISS

Farmegra
VEGA GROUP COMPANY

VEMAX PHARMA


UNCG
UDRUŽENJE NEUROLOGA CRNE GORE
20
OBNOVA NEZAVISNOSTI CRNE GORE
2006–2026
55
CRNOGORSKA AKADEMIJA NAUKA I UMJETNOSTI
1971–2026
2006
2026
DA JE VJEČNA CRNA GORA